跳至主要内容
临床试验/JPRN-UMIN000004919
JPRN-UMIN000004919已完成1 期

Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study) - Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study)

Chiba Tokushukai Hospital0 个研究点目标入组 30 人开始时间: 2011年1月20日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Pregnancy 2.Lactation 3.Patients having will of pregnancy. 4.Patients have uncontrollable severe infectional diseases. 5.Patients who are treated with steroid or immunotherapy during clinical trial. 6.Patients have uncontrollable associated cancer. 7.Patients who have non-recovered injury. 8.Patients judged inappropriated by doctors.

研究者

相似试验